Alan S. Roemer

Alan S. Roemer has served as chairman and a member of the board of directors since September 2020. Mr. Roemer has served on the board and as the chair of the audit committee of board of NextImmune, Inc., a biotechnology company, since March 2017 and as the chair of the board of UTILITY therapeutics Ltd., a private biotechnology company, since March 2020. Mr. Roemer was the founding member and Senior Vice President of Roivant Sciences, Inc., a private biopharmaceutical company, from May 2014 to August 2019, where he held various senior management roles responsible for finance, operations and corporate development. From March 2015 to August 2015, he also served as principal financial and accounting officer of Axovant Sciences Ltd., a public biopharmaceutical company, and chief financial officer of its wholly owned subsidiary, Axovant Sciences, Inc. Mr. Roemer also served as a member of the board of directors of SomPharmaceuticals SA, a private biopharmaceutical company, from August 2012 to May 2016, until its acquisition by Amryt Pharma plc. Prior to Axovant, Mr. Roemer served in various roles, including managing director of the Trout Group LLC and Trout Capital LLC from 2009 to 2014, chief financial officer and treasurer of Zelos Therapeutics, Inc. from 2008 to 2009, and vice president of Pharmasset, Inc. 1998 to 2008, which was subsequently acquired by Gilead Sciences, Inc. Mr. Roemer has also served as a member of the business advisory board of Envisagenics, Inc., a private artificial intelligence company, since March 2020, and a member of the Board of Trustees of the Helene Fuld College of Nursing since June 2014. Mr. Roemer received a B.S. in Business Administration from Georgetown University and his MBA and MPH degrees from Emory University’s Goizueta Business School and Rollins School of Public Health.